In numerous clinical phase 2/3 trials, the combination of EGFR-TKIs and bevacizumab has consistently shown a significant enhancement in progression-free survival (PFS) compared to EGFR-TKIs monotherapy when used as the primary treatment for patients with EGFRm NSCLC (9–11). This evidence concerns the gene EGFR and non-small cell lung carcinoma.